PT  - JOURNAL ARTICLE
AU  - Laura C. Coates
AU  - Joseph F. Merola
AU  - Suzanne M. Grieb
AU  - Philip J. Mease
AU  - Kristina Callis Duffin
TI  - Methotrexate in Psoriasis and Psoriatic Arthritis
AID  - 10.3899/jrheum.200124
DP  - 2020 Jun 01
TA  - The Journal of Rheumatology
PG  - 31--35
VI  - 96
4099  - http://www.jrheum.org/content/96/31.short
4100  - http://www.jrheum.org/content/96/31.full
SO  - J Rheumatol2020 Jun 01; 96
AB  - Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.